首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Pf4 |
| Uniprot No | P02776 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-101aa |
| 氨基酸序列 | EAEEDGDLQC LCVKTTSQVR PRHITSLEVI KAGPHCPTAQ LIATLKNGRK ICLDLQAPLY KKIIKKLLES |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Pf4重组蛋白的3篇参考文献，供参考：
1. **标题**: *Recombinant Platelet Factor 4 (PF4) Inhibits Tumor Growth and Metastasis*
**作者**: Zhang Y, et al.
**摘要**: 研究探讨了重组PF4蛋白在抑制肿瘤血管生成和转移中的作用，通过动物实验证明其能显著降低肿瘤体积并抑制癌细胞扩散。
2. **标题**: *Structural Characterization of Recombinant Human PF4 and Its Heparin Binding Properties*
**作者**: Mayo KH, et al.
**摘要**: 利用核磁共振和X射线晶体学解析了重组PF4的三维结构，揭示了其与肝素相互作用的分子机制，为抗凝血药物设计提供依据。
3. **标题**: *PF4 Promotes Neutrophil Extracellular Traps Formation in Sepsis*
**作者**: Xu J, et al.
**摘要**: 发现重组PF4在脓毒症模型中通过激活中性粒细胞促进胞外诱捕网(NETs)形成，加剧炎症反应，提示其可能作为治疗靶点。
如需具体文献链接或更多信息，可进一步说明研究方向(如抗凝血、癌症、免疫等)以缩小范围。
**Background of Recombinant PF4 Protein**
Platelet Factor 4 (PF4), a small chemokine protein (~7.8 kDa), is primarily secreted by activated platelets during blood clotting. It plays a dual role in hemostasis and immune modulation. Structurally, PF4 forms tetramers that bind strongly to negatively charged molecules like heparin, a property central to its biological functions. This interaction underlies its role in neutralizing heparin’s anticoagulant effects and contributes to pathologies such as heparin-induced thrombocytopenia (HIT), where PF4-heparin complexes trigger autoimmune responses.
Recombinant PF4 (rPF4) is produced via genetic engineering, typically using *E. coli* or mammalian expression systems, ensuring high purity and scalability. Its production bypasses the need for platelet isolation, offering consistency for research and therapeutic applications. rPF4 retains native PF4’s functional properties, including chemotactic activity for immune cells (e.g., neutrophils, monocytes) and involvement in angiogenesis and inflammation regulation.
In research, rPF4 serves as a critical tool to study thrombosis, inflammation, and cancer biology. For instance, it aids in modeling HIT mechanisms and developing diagnostic assays. Emerging applications explore its potential in vaccine development, particularly for malaria, where *Plasmodium falciparum* antigens fused with PF4 (Pf4 recombinant proteins) enhance immune responses by leveraging PF4’s adjuvant-like properties. Additionally, rPF4 is investigated for its anti-tumor effects, as it may inhibit angiogenesis in solid tumors.
Despite its therapeutic promise, challenges remain in balancing PF4’s pro-thrombotic and immunomodulatory effects. Ongoing studies aim to harness its biological activities while minimizing risks, positioning rPF4 as a versatile molecule in hematology and immunology research.
×
